Adamas Pharmaceuticals ( ADMS ) recently announced their Q2 earnings report that disclosed that the company beat on GAAP EPS by $0.12, but missed by $0.11M on revenue. During the earnings call, the company publicized their two priorities for the remainder of 2019. One, driving towards th...

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Peter Vozzo - Westwicke Partners Gregory Went - Founder, Chairman and Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Alfred Merriweat...

Adamas Pharma (NASDAQ: ADMS ): Q2 GAAP EPS of -$0.90 beats by $0.12 . Revenue of $12.69M (+67.6% Y/Y) misses by $0.11M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,